Article
CNBC
(2020)
The trials, called ACTIV-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly's experimental treatment known as LY-CoV555, which is being developed in partnership with Canadian biotech company AbCellera.
.png?locale=en "Created by CourseChunks App")
CourseChunks
updated 6 months ago
0 likes
Comments
RELATED RESOURCES
with chunks in common
MORE RELATED CONTENT
with shared categories
MORE RESOURCES FROM SOURCE
More from Resources from Summit Global Education CNBC
No comments yet. Be the first to comment!